NurExone Biologic (FRA:J90) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.29
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic OCF Margin %?

NurExone Biologic FRA:J90 -8.98% 34 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, NurExone Biologic ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. NurExone Biologic's Cash Flow from Operations for the three months ended in Mar. 2026 was €-1.07 Mil. NurExone Biologic's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, NurExone Biologic's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, NurExone Biologic's current OCF Yield % is -12.71%.

The historical rank and industry rank for NurExone Biologic's OCF Margin % or its related term are showing as below:


FRA:J90's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

NurExone Biologic OCF Margin % Related Terms

NurExone Biologic OCF Margin % Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic OCF Margin % Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 0.00 0.00

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

NurExone Biologic's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.852/0
= %

NurExone Biologic's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.069/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
NurExone Biologic (FRA:J90) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NurExone Biologic and its competitors. According to the industry distribution chart, NurExone Biologic ranks #999999 out of 959 companies in the Biotechnology industry.
Is NurExone Biologic's OCF Margin % too high?
NurExone Biologic's current OCF Margin % is 0.00%. Based on the distribution chart, NurExone Biologic ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #999999 out of 959 companies for OCF Margin %. This places NurExone Biologic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price